Gómez-Rivera N, Gómez-Jiménez IA, Fonseca-Chon I, García-Zárate MG, Gómez-Figueroa CO, Villalobos-García L, de la Herrán-Villapudua MS

Language: Spanish
References: 16
Page: 8-12
PDF size: 271.37 Kb.

ABSTRACT

Objective: To describe the frequency and factors related to mortality in children with Rocky Mountain fever spotted (RMSF) treated for 14 years at the Hospital Infantil del estado de Sonora. Material and methods: This is a retrospective cohort of 203 children, treated between 2003 and 2016. Clinical and laboratory data were compared between patients who died and those who survived. Chi-square and Student’s t were used for comparison between groups; a p value ‹0.05 was considered statistically significant. Results: The overall mortality was 26.6%, in the period 2003-2008 happened the highest number of deaths, up to 66% in one year. In recent years, mortality has decreased to 14.3%. Statistically significant clinical features of poor prognosis were: edema of wrists, vasculitis, abdominal pain, renal failure and elevation of transaminases (SGOT and TGP). In recent years, the time of antibiotic initiation has decreased, but it has not been achieved on average ≤ 5 days. Conclusions: In children with RMSF, in this 14-year experience, an important decrease in mortality has been observed; however, more efforts should be made to achieve mortality between 3 and 7%, as has already been reported.

REFERENCES

1. Gómez N, Álvarez G, García M, Fonseca I, Cano M, Villalobos L et al. Fiebre manchada de las Montañas Rocosas en niños. Informe de 18 casos. Rev Mex Pediatr. 2009; 76(6): 245-250.

2. Mukkada S, Buckingham S. Recognition prompt treatment for tick- borne infections in children. Infect Dis Clin N Am. 2015; 29: 539-555.

3. Zientek J, Dahlgren S, McQuiston J, Regan J. Self-reported treatment practices by healthcare providers could lead to death from Rocky Mountain Spotted Fever. J Pediatr. 2014; 164: 416-418.

4. Centers for Disease Control and Prevention. Fatal cases of rocky mountain spotted fever in family clusters-Three States, 2003. MMWR. 2004; 53: 407.

5. Gómez N, Álvarez G, García M, Fonseca I, Villalobos L, Cano M. Fiebre manchada de las montañas rocosas en niños: experiencia hospitalaria. Rev Mex Pediatr. 2013; 80(6): 227-231.

6. Gómez N, Fonseca I, García M, Gómez C, Villalobos L. Contraste entre dos esquemas de antibióticos en niños con choque séptico por «fiebre manchada de las Montañas Rocosas». Rev Mex Pediatr. 2014; 81(6): 204-220.

7. Dellinger R. Surviving sepsis campaing. international guidelines for management of severe sepsis and septic shock. Crit Care Med. 2008; 36: 296-227.

8. Masters E, Olson G, Weiner S, Paddock C. Rocky mountain spotted fever. A clinician’s dilemma. Arch Intern Med. 2003; 163: 769-774.

9. Buckingham S, Marshall G, Gordon E, Schutze G, Woods C, Jackson M et al. Clinical and laboratory features, hospital course, and outcome of rocky mountain spotted fever in children. J Pediatr. 2007; 150: 180-184.

10. Wood D, Wood R, Tucker A. Genetic systems for studying obligate intracellular pathogens: an update. Curr Opin Microbiol. 2014; 17: 11–16.

11. Bermúdez S, Lyons R, García G, Zaldíva L, Arteaga G. Serologic evidence of human Rickettsia infection found in three locations in Panamá. 2013; 33: 31-37.

12. Bozar R. La fiebre manchada de las montañas rocosas en Costa Rica, una alerta al personal de salud. Acta Médica Costarricense. 2008; 50: 75-76.

13. De Lara J, Cárdenas R. Fiebre manchada de las montañas rocosas en pediatría. Revisión clínica de una serie de 115 casos. Revista de Enfermedades Infecciosas en Pediatría. 2008; 22: 4-9.

14. Field J, Seijo L. Rickettsiosis en baja california. Bol Clin Hosp Infant Edo Son. 2011; 28: 44-50.

15. Tull R, Ahn C, Daniel A, Yosipovitch G, Strowd L. Retrospective study of rocky mountain spotted fever in children. Pediatric Dermatology. 2017; 34: 119-123.

16. Kimberlin D, Brady M, Jackson M. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.